X4 Pharmaceuticals, Inc. (XFOR) — Financial statements
Income statement, balance sheet, and cash flow for X4 Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 35↑1273.2% | 3 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 6↑685.1% | 0.80 | 0.00 | 0.00↓100.0% | 2 | |
| Gross Profit | 29↑1539.5% | 2 | 0.00 | 0.00↑100.0% | -2 | |
| Operating Expenses | ||||||
| R&D Expenses | 72↓11.5% | 82↑13.4% | 72↑17.9% | 61↑25.2% | 49 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 44↓29.3% | 62↑73.3% | 36↑31.4% | 27↑9.4% | 25 | |
| Other Expenses | 0.00↑100.0% | -105 | 0.00↑100.0% | -0.51 | 0.00 | |
| Operating Expenses | 116↑203.3% | 38↓64.5% | 108↑22.8% | 88↑19.2% | 73 | |
| Total Costs & Expenses | 122↑213.1% | 39↓63.8% | 108↑22.8% | 88↑16.2% | 75 | |
| Operating Results | ||||||
| Operating Income | -87↓138.7% | -36↑66.1% | -108↓22.8% | -88↓16.2% | -75 | |
| Depreciation & Amortization | 1↑60.4% | 0.80↑90.0% | 0.42↓18.3% | 0.51↓72.9% | 2 | |
| EBITDA | -86↓210.4% | -28↑70.9% | -95↓6.2% | -89↓21.6% | -73 | |
| EBIT | -87↓206.2% | -28↑70.2% | -95↓6.1% | -90↓19.2% | -75 | |
| Interest & Other Income | ||||||
| Net Interest Income | -4↓43.4% | -3↓151.0% | -1↑68.3% | -4↓3.9% | -4 | |
| Interest Income | 5↓20.7% | 6↑25.9% | 5↑1992.2% | 0.22↑2090.0% | 0.01 | |
| Interest Expense | 9↑1.2% | 9↑51.8% | 6↑44.7% | 4↑9.6% | 4 | |
| Non-Operating Income | 0.00↑100.0% | -8↑34.2% | -12↓636.2% | 2 | 0.00 | |
| Other Income / Expenses | 8↑1145.3% | -0.74↓111.5% | 6↑202.6% | -6↑53.0% | -13 | |
| Income Before Tax | -79↓113.1% | -37↑63.3% | -101↓7.7% | -94↓5.8% | -89 | |
| Income Tax Expense | 0.04↓86.8% | 0.31↑297.4% | 0.08↑178.6% | 0.03↑64.7% | 0.02 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -79↓111.5% | -37↑63.0% | -101↓7.8% | -94↓5.8% | -89 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -79↓111.5% | -37↑63.0% | -101↓7.8% | -94↓5.8% | -89 | |
| Bottom-Line Net Income | -79↓111.5% | -37↑63.0% | -101↓4.9% | -96↑6.1% | -103 | |
| EPS (Basic) | -1.87↑66.5% | -5.59↑67.3% | -17.07↑62.6% | -45.60↑61.9% | -119.58 | |
| EPS (Diluted) | -1.87↑66.5% | -5.59↑67.3% | -17.07↑62.6% | -45.60↑61.9% | -119.58 | |
| Weighted Average Shares | 42↑531.0% | 7↑13.1% | 6↑179.9% | 2↑146.7% | 0.86 | |
| Weighted Average Diluted Shares | 42↑531.0% | 7↑13.1% | 6↑179.9% | 2↑146.7% | 0.86 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.